Jan 11 (Reuters) - CMS:
* U.S. GOVERNMENT MEDICARE PROGRAM PLANS TO COVER ALZHEIMERS TREATMENTS INCLUDING BIOGEN'S ADUHELM WITH CONDITIONS
* U.S. GOVERNMENT MEDICARE PROGRAM PROPOSES THAT COMPANIES MAKING ALZHEIMERS DRUGS MUST RUN ADDITIONAL TRIALS Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.